I asked my buddy ChatGPT after today's news on leronlimab, how much better is it than Trovdely fighting cancer.
As of May 13, 2025, both Leronlimab and Trodelvy (sacituzumab govitecan-hziy) are under investigation for their efficacy in treating various cancers, including metastatic triple-negative breast cancer (mTNBC). Here's a comparison based on the most recent data:
Urology Times
Applied Clinical Trials
Docwire News
Leronlimab
Mechanism of Action: Leronlimab is a CCR5 antagonist. Recent findings suggest it may convert "cold" tumors (those less responsive to immunotherapy) into "hot" tumors, potentially enhancing the immune system's ability to attack cancer cells.
Yahoo Finance
Clinical Trials: The FDA has approved a Phase 2 trial to evaluate Leronlimab's safety and efficacy in patients with microsatellite-stable metastatic colorectal cancer (mCRC). This trial will assess overall response rate, overall survival, safety, and tolerability when combined with other therapies.
Cancer Network
Targeted Oncology
Targeted Oncology
mTNBC Observations: In mTNBC patients, Leronlimab has shown promising survival outcomes. Observed survival rates at 12, 24, and 36 months post-treatment compare favorably with existing therapies. Notably, some patients who had exhausted other treatments survived more than 36 months after receiving Leronlimab and currently show no evidence of disease.
CytoDyn Inc.
+1
Clinical Trial Vanguard
+1
Trodelvy (Sacituzumab Govitecan-hziy)
Mechanism of Action: Trodelvy is a TROP2-directed antibody-drug conjugate (ADC) that delivers chemotherapy directly to cancer cells, minimizing damage to healthy cells.
Reuters
+2
Targeted Oncology
+2
Applied Clinical Trials
+2
Clinical Trials: In the Phase 3 ASCENT-04/KEYNOTE-D19 study, Trodelvy combined with Keytruda (pembrolizumab) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients with previously untreated, PD-L1-positive mTNBC.
Clinical Trial Vanguard
+5
Applied Clinical Trials
+5
Cancer Network
+5
Real-World Data: A retrospective analysis showed that Trodelvy maintained consistent efficacy and safety in real-world settings for patients with mTNBC, with median overall survival of 11.3 months and median PFS of 5.0 months.
Targeted Oncology
Comparison Summary
Efficacy: Trodelvy has demonstrated statistically significant improvements in PFS in both clinical trials and real-world settings. Leronlimab has shown promising survival outcomes in mTNBC patients, with some achieving long-term survival.
CytoDyn Inc.
Approval Status: Trodelvy is FDA-approved for certain breast cancer indications. Leronlimab is currently under investigation in Phase 2 trials for mCRC and has shown potential in mTNBC.
OncLive
+6
Targeted Oncology
+6
Cancer Network
+6
Safety Profiles: Trodelvy's common side effects include neutropenia and diarrhea. Leronlimab has been associated with a favorable safety profile, with minimal adverse events reported in studies.
Conclusion
While Trodelvy has established efficacy and is FDA-approved for specific breast cancer treatments, Leronlimab is emerging as a promising candidate, especially for patients with limited treatment options. Further clinical trials and peer-reviewed studies are necessary to fully ascertain Leronlimab's efficacy and potential advantages over existing therapies like Trodelvy.
As of May 13, 2025, both Leronlimab and Trodelvy (sacituzumab govitecan-hziy) are under investigation for their efficacy in treating various cancers, including metastatic triple-negative breast cancer (mTNBC). Here's a comparison based on the most recent data:
Urology Times
Applied Clinical Trials
Docwire News
Leronlimab
Mechanism of Action: Leronlimab is a CCR5 antagonist. Recent findings suggest it may convert "cold" tumors (those less responsive to immunotherapy) into "hot" tumors, potentially enhancing the immune system's ability to attack cancer cells.
Yahoo Finance
Clinical Trials: The FDA has approved a Phase 2 trial to evaluate Leronlimab's safety and efficacy in patients with microsatellite-stable metastatic colorectal cancer (mCRC). This trial will assess overall response rate, overall survival, safety, and tolerability when combined with other therapies.
Cancer Network
Targeted Oncology
Targeted Oncology
mTNBC Observations: In mTNBC patients, Leronlimab has shown promising survival outcomes. Observed survival rates at 12, 24, and 36 months post-treatment compare favorably with existing therapies. Notably, some patients who had exhausted other treatments survived more than 36 months after receiving Leronlimab and currently show no evidence of disease.
CytoDyn Inc.
+1
Clinical Trial Vanguard
+1
Trodelvy (Sacituzumab Govitecan-hziy)
Mechanism of Action: Trodelvy is a TROP2-directed antibody-drug conjugate (ADC) that delivers chemotherapy directly to cancer cells, minimizing damage to healthy cells.
Reuters
+2
Targeted Oncology
+2
Applied Clinical Trials
+2
Clinical Trials: In the Phase 3 ASCENT-04/KEYNOTE-D19 study, Trodelvy combined with Keytruda (pembrolizumab) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients with previously untreated, PD-L1-positive mTNBC.
Clinical Trial Vanguard
+5
Applied Clinical Trials
+5
Cancer Network
+5
Real-World Data: A retrospective analysis showed that Trodelvy maintained consistent efficacy and safety in real-world settings for patients with mTNBC, with median overall survival of 11.3 months and median PFS of 5.0 months.
Targeted Oncology
Comparison Summary
Efficacy: Trodelvy has demonstrated statistically significant improvements in PFS in both clinical trials and real-world settings. Leronlimab has shown promising survival outcomes in mTNBC patients, with some achieving long-term survival.
CytoDyn Inc.
Approval Status: Trodelvy is FDA-approved for certain breast cancer indications. Leronlimab is currently under investigation in Phase 2 trials for mCRC and has shown potential in mTNBC.
OncLive
+6
Targeted Oncology
+6
Cancer Network
+6
Safety Profiles: Trodelvy's common side effects include neutropenia and diarrhea. Leronlimab has been associated with a favorable safety profile, with minimal adverse events reported in studies.
Conclusion
While Trodelvy has established efficacy and is FDA-approved for specific breast cancer treatments, Leronlimab is emerging as a promising candidate, especially for patients with limited treatment options. Further clinical trials and peer-reviewed studies are necessary to fully ascertain Leronlimab's efficacy and potential advantages over existing therapies like Trodelvy.
2
